Brief: Pilot Randomized Controlled Trial Validates Daxor Bva-100® Diagnostic For Heart Failure Patients
23/03/2023 13:12
March 23 (Reuters) - Daxor Corp DXR.O :
* PILOT RANDOMIZED CONTROLLED TRIAL VALIDATES DAXOR BVA-100®
DIAGNOSTIC FOR HEART FAILURE PATIENTS
Source text for Eikon: ID:nGNX4XnmC2
Further company coverage: DXR.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Daxor
See all newsNASDAQ RESUMED AT 02:03 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:58 PM
Brief: Daxor Corp Reaffirms Focus On Blood Volume Analysis Technology
Brief: Daxor Corporation Submits 510(K) To FDA For Next-Generation Blood Volume Analyzer
Brief: Daxor Corporation Streamlines Regulatory Strategy For Groundbreaking Diagnostic Device